Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, et al
767-p: a phase 1b/2a study of the safety and tolerability of gsbr-1290, a novel oral small molecule glucagon-like peptide 1 receptor agonist (glp-1ra), in healthy overweight/obese volunteers (hov) and participants with type 2 diabetes mellitus (t2dm)
Long-standing diabetes often damages nerves, most visibly as numbness in the feet or problems with balance, but it can also affect the autonomic nerves that help coordinate erections
With each injection I get slight nausea, as expected, but otherwise feeling good
The following paragraphs provide an update of the recent findings on the mechanisms of lipotoxicity in NAFLD
Takes Time to See Results Most people notice real changes in 8 to 12 weeks